Small molecule discovery



Drug discovery steps



Screening assays



Robotics



NIH National Center for Advancing Translational Sciences

HTS assays



Coussens, N. P., Braisted, J. C., Peryea, T., Sittampalam, S. G., Simeonov, A. and Hall, M. D. **Small Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of FDA-Approved Drugs** *Pharmacological Reviews*, October 2017, 69 (4) 479-496

Assay expense

Important Considerations for Choosing an Assay

- **Assay expense**
  - Cost per well
  - Disposal cost(s)

Instrumentation

Important Considerations for Choosing an Assay

- Assay expense
  - Cost per well
  - Disposal cost(s)
- **Available instrumentation**
  - **Select the best possible assays based on the available instrumentation**

Throughput

Important Considerations for Choosing an Assay

- Assay expense
  - Cost per well
  - Disposal cost(s)
- Available instrumentation
  - Select the best possible assays based on the available instrumentation
- **Assay throughput**
  - **Miniaturization reduces the cost per well**

Miniaturization

Assay Miniaturization Saves Time and Reagents





	96	384	1536
Plates per 100,000 compounds:	1,042	261	66
Assay volume (uL):	50-200	30-50	2-8
Adherent cell seeding density:	~10,000	~2,000	~500

Horman, Shane R. "Complex High-Content Phenotypic Screening." Special Topics in Drug Discovery. InTech, 2016.

Multiplex

Important Considerations for Choosing an Assay

- Assay expense
  - Cost per well
  - Disposal cost(s)
- Available instrumentation
  - Select the best possible assays based on the available instrumentation
- Assay throughput
  - Miniaturization reduces the cost per well
- **Ability to multiplex**
  - **Can the response be measured by a single parameter; is multiparametric output possible?**
  - **Increased data per sample**
  - **Can guide hit slection by differentiating selectivity among related targets**
  - **Can distinguish pathway inhibition from cytotoxicity in a cell-based assay**

Reagents

Important Considerations for Choosing an Assay

- Assay expense
  - Cost per well
  - Disposal cost(s)
- Available instrumentation
  - Select the best possible assays based on the available instrumentation
- Assay throughput
  - Miniaturization reduces the cost per well
- Ability to multiplex
  - Can the response be measured by a single parameter; is multiparametric output possible?
  - Increased data per sample
  - Can guide hit slection by differentiating selectivity among related targets
  - Can distinguish pathway inhibition from cytotoxicity in a cell-based assay
- **Reagents**
  - **Stablility for hours is important**
  - **Consistency is critical (ideally obtain a large quantity from a single lot)**
  - **All reagents need to be validated (cell lines, antibodies, enzymatic purity, etc.)**

Interference

Important Considerations for Choosing an Assay

- **Assay expense**
  - Cost per well
  - Disposal cost(s)
- **Available instrumentation**
  - Select the best possible assays based on the available instrumentation
- **Assay throughput**
  - Miniaturization reduces the cost per well
- **Ability to multiplex**
  - Can the response be measured by a single parameter; is multiparametric output possible?
  - Increased data per sample
  - Can guide hit slection by differentiating selectivity among related targets
  - Can distinguish pathway inhibition from cytotoxicity in a cell-based assay
- **Reagents**
  - Stablility for hours is important
  - Consistency is critical (ideally obtain a large quantity from a single lot)
  - All reagents need to be validated (cell lines, antibodies, enzymatic purity, etc.)
- **Potential for assay interference**
  - **Fluorescent compounds can interfere with fluorescent readouts**
  - **Colored compounds might interfere with luminescence**

Spectroscopic profiling



Simeonov, A., Jadhav, A., Thomas, C.J., Wang, Y., Huang, R., Southall, N.T., Shinn, P., Smith, J., Austin, C.P., Auld, D.S. and Inglese, J., 2008. **Fluorescence spectroscopic profiling of compound libraries.** *Journal of Medicinal Chemistry*, 51(8), 2363-2371.

Tolerance to DMSO

Determination of Assay Tolerance to DMSO/Vehicle is Important





Yasgar A., Jadhav A., Simeonov A., Coussens N.P., **AlphaScreen-Based Assays: Ultra-High-Throughput Screening for Small-Molecule Inhibitors of Challenging Enzymes and Protein-Protein Interactions**. *Methods Mol Biol*. 2016;1439:77-98.

Homogenous format

Important Considerations for Choosing an Assay

- **Homogenous assay format is preferred for screening**
  - Add reagents, mix and measure (no solution removal or wash steps)
  - Automation friendly
  - Reduces variability
  - Decreases hands-on time
  - Improves reproducibility

Time required

Important Considerations for Choosing an Assay

- Homogenous assay format is preferred for screening
  - Add reagents, mix and measure (no solution removal or wash steps)
  - Automation friendly
  - Reduces variability
  - Decreases hands-on time
  - Improves reproducibility
- **Time required for assay**
  - **Off-line reagent preparation**
  - **Is temperature equilibration required**
  - **Actual assay time**
  - **Kinetic versus end point read**
  - **Time required for data analysis and record keeping**

Signal stability

Important Considerations for Choosing an Assay

- **Homogenous assay format is preferred for screening**
  - Add reagents, mix and measure (no solution removal or wash steps)
  - Automation friendly
  - Reduces variability
  - Decreases hands-on time
  - Improves reproducibility
- **Time required for assay**
  - Off-line reagent preparation
  - Is temperature equilibration required
  - Actual assay time
  - Kinetic versus end point read
  - Time required for data analysis and record keeping
- **Signal stability**
  - **Does the response occur rapidly or within a few minutes or hours?**
  - **Longer signal stability allows for flexibility in automated systems**
  - **Longer signal stability minimizes differences among plates within a stack**

Sensitivity

Important Considerations for Choosing an Assay

- **Homogenous assay format is preferred for screening**
  - Add reagents, mix and measure (no solution removal or wash steps)
  - Automation friendly
  - Reduces variability
  - Decreases hands-on time
  - Improves reproducibility
- **Time required for assay**
  - Off-line reagent preparation
  - Is temperature equilibration required
  - Actual assay time
  - Kinetic versus end point read
  - Time required for data analysis and record keeping
- **Signal stability**
  - Does the response occur rapidly or within a few minutes or hours?
  - Longer signal stability allows for flexibility in automated systems
  - Longer signal stability minimizes differences among stacks of plates
- **Assay Sensitivity**
  - **Choice of readouts is important**
    - **Colorimetric<fluorescent<luminescent**

Evaluating assay

Evaluating Assay Suitability for Screening



S/N = 12

S/B = 5

z = 0.5

S/N = 27

S/B = 10

z = 0.1

$$S/N = \frac{\text{mean signal} - \text{mean background}}{\text{standard deviation of background}}$$

$$S/B = \frac{\text{mean signal}}{\text{mean background}}$$

$$Z = 1 - \frac{3\text{SD of sample} + 3\text{SD of control}}{|\text{mean of sample} - \text{mean of control}|}$$

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Zhang JH, Chung TD, Oldenburg KR. J Biomol Screen. 1999;4(2):67-73.

Suitability

Evaluating Assay Suitability for Screening



$$Z = 1 - \frac{3SD \text{ of sample} + 3SD \text{ of control}}{|\text{mean of sample} - \text{mean of control}|}$$ *

Z-factor value	*Structure of assay*	*Related to screening*
1	SD = 0 (no variation), or the dynamic range → ∞	An ideal assay
$1 > Z \geq 0.5$	Separation band is large	An excellent assay
$0.5 > Z > 0$	Separation band is small	A double assay
0	No separation band, the sample signal variation and control signal variation bands touch	A "yes/no" type assay
<0	No separation band, the sample signal variation and control signal variation bands overlap	Screening essentially impossible

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Zhang JH, Chung TD, Oldenburg KR. J Biomol Screen. 1999;4(2):67-73.

Quantitative HTS

Improving the Process of Early Discovery: Quantitative High-Throughput Screening (qHTS)



- Conventional screening done at one concentration
  - Not appropriate for potency testing – "dose makes the poison"
- qHTS tests compounds assayed at multiple concentrations (range: 4 logs)
- Enabled by miniaturized assay volumes (2-8 µL per test) and informatics pipeline
- Generates *pharmacological actives* instead of statistical "hits"
  - Dramatically increases reliability
  - Dramatically reduces false positives and false negatives

PNAS 103:11473

- *To date, several hundred million datapoints from several hundred screens have been generated and deposited in the public domain.*

Medicinal chemistry



Tier 1: Synthesis & validation
- Medicinal chemistry
- Purification
- In vitro ADME

Tier 2: Compound profile expansion
- Met ID/CYP studies
- In vitro toxicology

Tier 3: Advanced Preclinical studies
- Formulation
- Scale-up
- In vivo PK/PD
- Preclinical toxicology





Drug combinations

Translation Challenge: Rapid Discovery of Drug Combinations



Robotic Arm



Destination Plate
(1536, screening)

Source Plate
(384, compounds)

1. Appropriate libraries

The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics

Ruili Huang,* Noel Southall,* Yuhong Wang, Adam Yasgar, Paul Shinn, Ajit Jadhav, Dac-Trung Nguyen, Christopher P. Austin†

Small-molecule compounds approved for use as drugs may be "repurposed" for new indications and studied to determine the mechanisms of their beneficial and adverse effects. A comprehensive collection of all small-molecule drugs approved for human use would be invaluable for systematic repurposing across human diseases, particularly for rare and neglected diseases, for which the cost and time required for development of a new chemical entity are often prohibitive. Previous efforts to build such a comprehensive collection have been limited by the complexities, redundancies, and semantic inconsistencies of drug naming within and among regulatory agencies worldwide; a lack of clear conceptualization of what constitutes a drug; and a lack of access to physical samples. We report here the creation of a definitive, complete, and nonredundant list of all approved molecular entities as a freely available electronic resource and a physical collection of small molecules amenable to high-throughput screening.

www.ScienceTranslationalMedicine.org 27 April 2011 Vol 3 Issue 80 80ps16

2. Automation/ screening technologies

Acoustic Dispensers

3. Informatics platform



NIH National Center for Advancing Translational Sciences

Resistance

Application of Drug Combinations to Address Resistance







Dissemination

Dissemination of technology: combination screening to overcome drug resistance in cancer cells

- Applied to ABC subtype of Diffuse Large B-Cell Lymphoma (ABC-DLBCL)
- Ibrutinib is a BTK inhibitor that has activity against ABC DLBCL
- Lead investigators: Craig Thomas (NCATS) and Louis Staudt (NCI)
- Study evaluated 459 drugs *in combination* with Ibrutinib
  - » 6 x 6 concentration-response "matrix blocks", validation in 10 x 10 concentration-response matrix blocks
- DNA-damaging agents identified as synergizing with Ibrutinib in killing ABC DLBCL cell lines
- **Dissemination:**
  - » Protocols
  - » Source code for dispense

High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell–like diffuse large B-cell lymphoma cells





PNAS 111, 2349-2354

NIH National Center for Advancing Translational Sciences

Triple drug combination

Example: triple drug combination screening to tackle resistance against artemisinin-based combination therapies in malaria

ACS Pharmacol. Transl. Sci. 2020, https://dx.doi.org/10.1021/acsptsci.0c00110?ref=pdf

① Drugs A and B are acoustically dispensed in a 10x10-well matrix,12 replicate blocks per plate. Single drug resonses, bottom row (Drug A) and right column (Drug B).



② To each replicate block, serial dilutions of Drugs C is acoustically dispensed, with the final block serving as a DMSO control



③ Plate view of triple combination screening plate with positive control (artesunate, blue) and neutral controls (DMSO, grey) also shown.

④ Dispense *P. falciparum* and erythrocytes, incubate 72 hr

⑤ Dispense 2 μL of SYBRGreen1 and lysis solution, incubate overnight. Fluorescence quantified



⑥ Parasite proliferation response is normalized to artesunate and DMSO controls. For each concentration Drug C block, response of Drug A + Drug B wells is summed.



⑦ Triple drug response is analyzed as a function of Drug C concentration.

VIPOR combination

U.S. National Library of Medicine
ClinicalTrials.gov

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

ViPOR Regimen Is Safe, Shows Impressive Activity in Relapsed/Refractory DLBCL

The 5-drug regimen of venetoclax (Venclexta), ibrutinib (Imbruvica), prednisone, obinutuzumab (Gazyva), and lenalidomide (Revlimid; ViPOR) showed a tolerable safety profile and encouraging antitumor activity with complete responses (CRs) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to phase 1b/2 findings that were presented during the 2020 ASH Annual Meeting and Exposition.

Results showed that of 52 evaluable patients, the best overall response was 71%, with a complete response (CR) rate of 52% and a 19% partial response (PR) rate. Specifically, in relapsed patients (n = 30), the objective response rate (ORR) was 80% with a 70% and 13% CR and PR rate, respectively. The ORR was 59% in refractory patients (n = 22), with a 27% CR rate and a 27% PR rate.

https://www.onclive.com/view/vipor-regimen-is-safe-shows-impressive-activity-in-relapsed-refractory-dlbcl

ViPOR Regimen Signals Benefit in Patients With Mantle Cell Lymphoma

Treatment with the ViPOR regimen consisting of venetoclax (Venclexta), ibrutinib (Imbruvica), prednisone, and lenalidomide (Revlimid), has thus far appeared safe for use in patients with mantle cell lymphoma (MCL) and has demonstrated preliminary activity.

Results from the phase 1 portion of the ViPOR study (NCT03223610) were presented during the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Of the 11 patients who were treated, the ORR was 100% and the complete remission (CR) rate was 80%. Nine patients were evaluable for safety and no dose-limiting toxicities were observed. There were few grade 3 and 4 adverse events (AEs), but the hematologic grade 3/4 AEs included neutropenia (13%), anemia (11%), and thrombocytopenia (9%). The non-hematologic grade 3/4 AEs included hypokalemia (33%) along with fatigue, hypomagnesemia, elevated bilirubin, atrial fibrillation, lung infection, and syncope occurring in 11% of patients each.

https://www.targetedonc.com/view/vipor-regimen-signals-benefit-in-patients-with-mantle-cell-lymphoma

NIH National Center for Advancing Translational Sciences

3D models


Increasing the predictivity of *in vitro* assays: a continuum of 3D models of healthy and diseased tissues
2D
Spheroids
Organoids
Printed Tissues
Organ-on-a-chip
Physiological complexity
HTS compatibility
NIH
National Center for Advancing Translational Sciences

Tissue bioprinting



3D tissue models

Current portfolio of engineered 3D tissue models



Program Director Marc Ferrer, Ph.D. https://ncats.nih.gov/bioprinting

NIH National Center for Advancing Translational Sciences

Skin biofabrication



Skin tissue generation



Tissue model

www.oncotarget.com Oncotarget, 2020, Vol. 11, (No. 27), pp: 2587-2596

Research Paper

A 3D biofabricated cutaneous squamous cell carcinoma tissue model with multi-channel confocal microscopy imaging biomarkers to quantify antitumor effects of chemotherapeutics in tissue



Collaboration between NCATS (Marc Ferrer) and Rockefeller University (Daniel Gareau)

NIH National Center for Advancing Translational Sciences

Information

Book

Sharing internal know-how: Assay Guidance Manual (47 chapters/ 1,338 printed pages)



Table of Contents

Website:https://ncats.nih.gov/expertise/preclinical/agm

Email us: NCATS_AGM_Editors@mail.nih.gov

Facebook: www.facebook.com/assayguide

LinkedIn

https://ncats.nih.gov/agm-video

August 7th Videos

1. Austin, CP: **Welcome to the Assay Guidance Manual (AGM) Workshop**
2. Coussens, NP: **Strategies for Assay Selection & Robust Biochemical Assays**
3. Riss, T: **Treating Cells as Reagents to Design Reproducible Screening Assays**
4. Trask, OJ: **Assay Development Considerations for High Content Imaging**
5. Auld, DS: **Studies in Mechanisms and Methods in Assay Interferences**
6. Dahlin, JL: **Assay Interference by Chemical Reactivity**
7. Chung, TDY: **Basic Assay Statistics, Data Analysis & Rules of Thumb**
8. Devanarayan, V: **Reproducibility & Differentiability of Potency Results**
9. Sittampalam, GS: **Avoiding Artifacts & Interferences in Assay Operations**

March 26-27th Videos

1. Austin, CP: **Welcome to the Assay Guidance Manual (AGM) Workshop**
2. Coussens, NP: **Robust Assays Define Success in Preclinical Research**
3. Lal-Nag, M: **Target Identification & Validation in Translational Discovery**
4. Foley, TL: **Development & Validation of Cell-Based and Biochemical Assays**
5. Riss, T: **Treating Cells as Reagents to Design Reproducible Screening Assays**
6. Trask, OJ: **Assay Development for HCS & Best Practices for 3D HCS**
7. Roth, KD: **Mass Spectrometry for Drug Screening and Lead Optimization**
8. Dahlin, JL: **Bioassay Interference by Aggregation and Chemical Reactivity**
9. Patnaik, S: **Lead Selection and Optimization by Medicinal Chemistry**
10. Xia, M: ***In Vitro* Toxicological Testing Using a qHTS Platform**
11. Xu, X: ***In Vitro* Assessment of ADME Properties of Lead Compounds**
12. Kahl, SD: **Statistical Design of Experiments for Assay Development**
13. Guha, R: **Pharos Application to Target Evaluation and Drug Discovery**
14. Weidner, JR: **Assay Operations: Keeping Assays Robust and Reproducible**

NIH National Center for Advancing Translational Sciences

Assay guidance manual

Assay Guidance Manual Training Workshops

- Online Training Modules
- Upcoming Workshops
- Past Workshops

NCATS offers a variety of Assay Guidance Manual (AGM) training workshops throughout the year designed to share best practices and advice on robust assay design, development and implementation for researchers involved in the drug discovery process.

Online Training Modules

NCATS offers an online AGM training workshop in addition to the in-person AGM workshops held throughout the year. The online training workshop also features experts sharing best practices and expert advice on assay design, development and implementation. View the video modules.

NIH National Center for Advancing Translational Sciences

Assay Guidance Workshop on 3D Tissue Models for Antiviral Drug Development

Tue Jun 7, 11:00 AM - Wed Jun 8, 5:15 PM (EDT)

Zoom

Add to calendar · Share

THIS EVENT HAS ENDED

Video of the workshop is available at the links below:

Assay Guidance Workshop on 3D Tissue Models for Antiviral Drug Development (Day 1) (June 7, 2022)

Assay Guidance Workshop on 3D Tissue Models for Antiviral Drug Development (Day 2) (June 8, 2022)

About the Workshop

The National Center for Advancing Translational Sciences (NCATS) Assay Guidance Manual (AGM) program is hosting a two-day workshop that will cover a broad range of critical concepts, including practical approaches and best practices, for developing standardized 3D cellular assays with the hope of helping the community to successfully develop therapeutics for future pandemic threats. This workshop is jointly organized by NCATS, the National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation. The overall goal of this workshop is to help scientists establish robust, reproducible, scalable, consistent, advanced 3D tissue models to study pandemic threat viruses.

https://ncats.nih.gov/expertise/preclinical/agm/training

NIH National Center for Advancing Translational Sciences

Biomedical changes

Joining forces



Biological assay development

Original Research

Cross-Platform Bayesian Optimization System for Autonomous Biological Assay Development

SLAS Technology
2021, Vol. 26(6) 579–590
© Society for Laboratory Automation and Screening 2021
DOI: 10.1177/24726303211053782
journals.sagepub.com/home/jla
SAGE

Sam Elder[1*], Carleen Klumpp-Thomas[2*], Adam Yasgar[2], Jameson Travers[2], Shayne Frebert[2], Kelli M. Wilson[2], Alexey V. Zakharov[2], Jayme L. Dahlin[2], Christoph Kreisbeck[1], Dennis Sheberla[1], Gurusingham S. Sittampalam[2], Alexander G. Godfrey[2], Anton Simeonov[2], and Sam Michael[2]

Graphical Abstract.

NCATS


NCATS
COLLABORATE. INNOVATE. ACCELERATE.
ncats.nih.gov
@ncats_nih_gov
@ncats.nih.gov
NIH-NCATS